RxDoctor Payments Data

Kirsten Oliver, PA

Physician Assistant · Utica, NYNPI 1285310573

Payments from drug & device makers

$1,759in general payments, 2019–2025

Across 76 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$340
  • AstraZeneca$312
  • Abiomed$251
  • Novartis$215
  • Pfizer$149
  • Merck$106
  • plus $386 from 12 others

What the payments were for

  • Food & beverage$1,759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,759 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$30,271
Medicare patients
229
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$111,008
EntrestoSacubitril/Valsartan39$48,824
XareltoRivaroxaban20$33,298
JardianceEmpagliflozin18$22,688
BrilintaTicagrelor24$15,300
Repatha SyringeEvolocumab17$11,177
Ranolazine ErRanolazine18$1,848
Metoprolol Succinate122$1,718
Amiodarone Hcl19$1,061
Rosuvastatin Calcium83$859
Bisoprolol Fumarate30$709
Atorvastatin Calcium40$557
Losartan Potassium54$487
Ezetimibe14$462
Carvedilol60$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$149$111,00899 claims
NovartisEntresto$215$48,82439 claims
Boehringer IngelheimJardiance$340$22,68818 claims
AstraZenecaBrilinta$312$15,30024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →